Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's executive management will deliver a corporate overview presentation on Tuesday, August 12, 2025, at 12:30 p.m. Eastern time.

Investors and interested parties can access the live audio webcast through Castle Biosciences' investor relations website at ir.castlebiosciences.com/events-presentations/. A replay of the presentation will be made available after the event.

News Market Reaction

-0.61%

1 alert

-0.61% News Effect

On the day this news was published, CSTL declined 0.61%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45^th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

When is Castle Biosciences (CSTL) presenting at the Canaccord Genuity Conference?

Castle Biosciences will present on Tuesday, August 12, 2025, at 12:30 p.m. Eastern time.

How can investors access Castle Biosciences' (CSTL) Canaccord conference presentation?

Investors can access the live audio webcast through Castle Biosciences' investor relations website at ir.castlebiosciences.com/events-presentations/. A replay will be available after the presentation.

What will Castle Biosciences (CSTL) discuss at the Canaccord Growth Conference?

The executive management will deliver a company overview at the conference.

Will there be a replay available of Castle Biosciences' (CSTL) Canaccord presentation?

Yes, a replay of the webcast will be available on the company's website following the conclusion of the live broadcast.